Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Evocalcet

An oral calcimimetic discovered in Japan and approved there in March 2018 for secondary hyperparathyroidism in patients on dialysis: it reduces the production of parathyroid hormone by the parathyroid glands. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?'Calcimimetic' means 'calcium-mimicking': the drug acts on the calcium receptors of the parathyroid glands and tricks them, as if there were more calcium in the blood, so they release less parathyroid hormone.

EvocalcetGo to the active ingredient →
EvocalcetActive ingredientEvocalcetCat. No. P-E144-001CAS 870964-67-3

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.